PARIS (Reuters) – Carmat, the artificial heart maker which this month got a 7 million euros ($7.40 million) lifeline to survive an imminent cash crunch, on Monday announced solid progress for its Aeson artificial heart device.
Carmat said it had performed seven Aeson implants as part of a clinical study in Paris and that it hoped to complete the study in 2025, in line with the company’s targets.
“This ramp-up is the result of growing experience in patient selection and attests to the steep learning curve of the surgical procedure,” said Professor Christian Latremouille, Director of Surgical Affairs at Carmat, in a press release.
The clinical study, called EFICAS, is a prospective study designed to include 52 patients eligible for transplants, currently enrolled by a network of six French cardiology centers, Carmat said.
The primary objective of the study is 180-day post-implantation survival without disabling stroke or successful heart transplant within 180 days of implantation, the company said.
The study also aims to assess state reimbursement of the device in France.
($1 = 0.9457 euros)
(Reporting by Sudip Kar-Gupta and Michal Aleksandrowicz; Editing by Jamie Freed and Janane Venkatraman)
